Go to the page content
Other

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

Locations

United States

Start date

06/02/2025

Identifiers

Trial ID NN7535-7976,
NCT number NCT06813924,
Eudract number Not Available

Summary

The study aims to test if a new medicine called etavopivat potentially affects other medicines in healthy participants. The purpose of the study is to investigate whether the use of etavopivat affects the breakdown and metabolism of commonly used medicines in the body. During the study, participants will receive etavopivat and five different medicines that are already approved and available on the market, and which can be prescribed by doctors. These marketed medicines are called substrate drugs and they are: digoxin, pitavastatin, metformin, midazolam, and rosuvastatin. During a period of the study, participants will take 2 tablets of etavopivat daily for 10 consecutive days. The study will last for about 34 to 64 days.

Trial Overview:

Condition

Healthy Volunteers Sickle Cell Disease, Thalassemia

Treatment

DRUG: Etavopivat

DRUG: Digoxin

DRUG: Pitavastatin

DRUG: Metformin

DRUG: Midazolam

DRUG: Rosuvastatin

Study type

INTERVENTIONAL

Trial duration

Feb 06 2025 - Jun 10 2025

Participants

29

Phase

I

Are you eligible?

Gender

Male and female

Age

18 to 55 years old

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.